⇨ Just 8 months after making its debut at the beginning of the year, Cambridge, MA-based Cue Biopharma has filed for a $40 million IPO. The TCR company is based on work done at Albert Einstein College of Medicine. The biotech window has opened considerably in the last few months, but a fledgling company like this could well test investors’ appetite for the unknown. According to the S-1, they’re still involved in preclinical work.
⇨ Gene editing companies arrived early on Wall Street, and now look to encourage investors with the latest animal data regarding CRISPR/Cas9. Intellia $NTLA today is touting “full 12-month data of its completed long-term mouse study, demonstrating robust and durable in vivo genome editing post single-dose, intravenous administration using its proprietary lipid nanoparticle delivery system.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.Free Subscription